This white paper, which is the 10th in a series intended to address issues associated with the development of therapeutic oligonucleotides, examines the subject of product-related impurities. The authors consider chemistry and safety aspects and advance arguments in favor of platform approaches to impurity identification and qualification. Reporting, identification, and qualification thresholds suitable for product-related impurities of therapeutic oligonucleotides are proposed.
Get full access to this article
View all access options for this article.
References
1.
AltonEW, BousheyHA, GarnH, GreenFH, HodgesM, MartinRJ, MurdochRD, RenzH, ShrewsburySB, et al. (2012). Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations. Nucleic Acid Ther, 22:246–254.
2.
KornbrustD, CavagnaroJ, LevinAA, FoyJ, PavcoP, Gamba-VitaloC and GuimondA. (2013). Oligo safety working group exaggerated pharmacology subcommittee consensus document. Nucleic Acid Ther, 23:21–28.
BermanCL, CannonK, CuiY, KornbrustDJ, LagruttaA, SunSZ, TepperJ, WaldronG and YounisHS. (2014). Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics. Nucleic Acid Ther, 24:291–301.
5.
CavagnaroJ, BermanC, KornbrustDJ, WhiteT, CampionS and HenryS. (2014). Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics. Nucleic Acid Ther, 24:313–325.
6.
HenrySP, SeguinR, CavagnaroJ, BermanC, TepperJ and KornbrustDJ. (2016). Considerations for the characterization and interpretation of results related to alternative complement activation in monkeys associated with oligonucleotide-based therapeutics. Nucleic Acid Ther, 26:210–215.
7.
BermanCL, BarrosSA, GallowaySM, KasperP, OlesonFB, PriestleyCC, SwederKS, SchlosserMJ and SobolZ. (2016). OSWG recommendations for genotoxicity testing of novel oligonucleotide-based therapeutics. Nucleic Acid Ther, 26:73–85.
8.
MarloweJL, AkopianV, KarmaliP, KornbrustDJ, LockridgeJ and SempleS. (2017). Recommendations of the oligonucleotide safety working group's formulated oligonucleotide oubcommittee for the safety assessment of formulated oligonucleotide-based therapeutics. Nucleic Acid Ther, 27:183–196.
9.
CapaldiDC, AckleyK, BrooksB, CarmodyJ, DraperK, KambhampatiR, KretschmerM, LevinD, McArdleJ, et al. (2012). Quality aspects of oligonucleotide drug development: specifications for active pharmaceutical ingredients. Drug Inf J, 46:611–626.
10.
CramerH, FinnKJ, and Sinha NDND. (2013). Oligonucleotide impurities and their origins. In: Analysis of Oligonucleotides and Their Related Substances. OkafoG, ElderD, WebbM, eds. ILM Publications, St Albans, pp. 21–100.
11.
BergotBJ and EganW. (1992). Separation of synthetic phosphorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange-high-performance liquid chromatography. J Chromatogr, 599:35–42.
12.
GausHJ, OlsenP, Van SooyK, RentelC, TurneyB, WalkerKL, McArdleJV and CapaldiDC. (2005). Trichloroacetaldehyde modified oligonucleotides. Bioorg Med Chem Lett, 15:4118–4124.
13.
CapaldiDC, GausHJ, CartyRL, MooreMN, TurneyBJ, DecottigniesSD, McArdleJV, ScozzariAN, RavikumarVT and KrotzAH. (2004). Formation of 4,4′-dimethoxytrityl-C-phosphonate oligonucleotides. Bioorg Med Chem Lett, 14:4683–4690.
14.
RentelCR. (2013). A control strategy for raw materials of oligonucleotide drug substances: application of ICH Q11. In: Podium Presentation at 15th Annual TIDES Conference, Boston, MA.
15.
CapaldiDC. (2014). Detecting and controlling oligonucleotide impurities. In: Podium Presentation at 14th Annual EuroTides Conference, Berlin, Germany.
16.
SeptakM. (1996). Kinetic studies on depurination and detritylation of CPG-bound intermediates during oligonucleotide synthesis. Nucleic Acids Res, 24:3053–3058.
17.
CapaldiDC. (2006). Identification of impurities in oligonucleotide therapeutics. In: Podium Presentation at 6th Annual EuroTides Conference, Hamburg, Germany.
18.
MorganMA, KazakovSA and HechtSM. (1995). Phosphoryl migration during the chemical synthesis of RNA. Nucleic Acids Res, 23:3949–3953.
19.
CalvittCJ, LevinDS, SheppardBT and GruenlohCJ. (2010). Chemistry at the 2′-position of constituent nucleotides controls degradation pathways of highly modified oligonucleotide molecules. Oligonucleotides, 20:239–251.
20.
CapaldiDC, GausH, KrotzAH, ArnoldJ, CartyRL, MooreMN, ScozzariAN, LoweryK, ColeD and RavikumarVT. (2003). Synthesis of high-quality antisense drugs. Addition of acrylonitrile to phosphorothioate oligonucleotides: adduct characterization and avoidance. Org Proc Res Dev, 7:832–838.
21.
RodriguezAA, CedilloI, MoweryBP, GausHJ, KrishnamoorthySS and McPhersonAK. (2014). Formation of the N2-acetyl-2,6-diaminopurine oligonucleotide impurity caused by acetyl capping. Bioorgan Med Chem Lett, 24:3243–3246.
22.
RodriguezAA, CedilloI and McPhersonAK. (2016). Conversion of adenine to 5-amino-4-pyrimidinylimidazole caused by acetyl capping during solid phase oligonucleotide synthesis. Bioorgan Med Chem Lett, 26:3468–3471.
23.
LorenzS, PrzybytekJ and SnobleK. (2009). Synthesis of oligonucleotides or phosphorothioate oligonucleotides with a capping reagent of N-methylimidazole free of 1, 3, 5-trimethylhexahydro-1, 3, 5-triazine. Patent WO2009052034, Honeywell International, Inc.
24.
RentelC, WangX, BattM, KurataC, OliverJ, GausHJ, KrotzAH, McArdleJV and CapaldiDC. (2005). Formation of modified cytosine residues in the presence of depurinated DNA. J Org Chem, 70:7841–7845.
HillKW. (2007). Understanding oligonucleotide production: identification of process-related impurities. In: Podium Presentation at DIA, 1st Oligonucleotide-Based Therapeutics Conference, Washington, DC.
27.
FlemingAM, MullerJG, DlouhyAC and BurrowsCJ. (2012). Structural context effects in the oxidation of 8-oxo-7,8-dihydro-2′-deoxyguanosine to hydantoin products: electrostatic, base stacking and base pairing. J Am Chem Soc, 134:15091–15102.
28.
ChenD, YanZ, ColeDL and SrivatsaGS. (1999). Analysis of internal (n-1)mer deletion sequences in synthetic oligodeoxyribonucleotides by hybridization to an immobilized probe array. Nucleic Acids Res, 27:389–395.
29.
FearonKL, StultsJT, BergotBJ, ChristensenLM and RaibleAM. (1995). Investigation of the ‘n–1’ impurity in phosphorothioate oligodeoxynucleotides synthesized by the solid-phase ß-cyanoethyl phosphoramidite method using stepwise sulfurization. Nucleic Acids Res, 23:2754–2761.
30.
TemsamaniJ, KubertM and AgrawalS. (1995). Sequence identity of the n-1 product of a synthetic oligonucleotide. Nucleic Acids Res, 23:1841–1844.
31.
KrotzAH, KlopchinPG, WalkerKL, SrivatsaGS, ColeDL and RavikumarVT. (1997). On the formation of longmers in phosphorothioate oligodeoxyribonucleotide synthesis. Tetrahedron Lett, 38:3875–3878.
32.
SuzikiT, OhsumiS and MakinoK. (1994). Mechanistic studies on depurination and apurinic site chain breakage in oligodeoxynucleotides. Nucleic Acids Res, 22:4997–5003.
33.
CapaldiDC and ScozzariAN. (2008).Manufacturing and analytical processes for 2′-O-(2-methoxyethyl)-modified oligonucleotides. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd edn. CrookeST, ed. CRC Press, Boca Raton, FL, pp. 401–434.
34.
SetlowRB and CarrierWL. (1966). Pyrimidine dimers in ultraviolet-irradiated DNAs. J Mol Biol, 17:237–254.
35.
DuttaS, ChowdhuryG and GatesKS. (2007). Interstrand cross-links generated by abasic sites in duplex DNA. J Am Chem Soc, 129:1852–1853.
36.
KurataC, BradleyK, GausH, LuuN, CedilloI, RavikumarVT, Van SooyK, McArdleJV and CapaldiDC. (2006). Characterization of high molecular weight impurities in synthetic phosphorothioate oligonucleotides. Bioorg Med Chem Lett, 16:607–614.
37.
CohenAS, VilenchikM, DudleyJL, GemborysMW and BourqueAJ. (1993). High-performance liquid chromatography and capillary gel electrophoresis as applied to antisense DNA. J Chromatogr A, 638:293–301.
38.
DeDionisioL. (1993). Capillary gel electrophoresis and the analysis of DNA phosphorothioates. J Chromatogr A, 652:101–108.
39.
MetelevV and AgrawalS. (1992). Ion-exchange high-performance liquid chromatography analysis of oligodeoxyribonucleotide phosphorothioates. Anal Biochem, 200:342–346.
40.
SrivatsaGS, KlopchinP, BattM, FeldmanM, CarlsonRH and ColeDL. (1997). Selectivity of anion exchange chromatography and capillary gel electrophoresis for the analysis of phosphorothioate oligonucleotides. J Pharm Biomed Anal, 16:619–630.
41.
ApffelA, ChakelJA, FischerS, LichtenwalterK and HancockWS. (1997). Analysis of oligonucleotides by HPLC-electrospray ionization mass spectrometry. Anal Chem, 69:1320–1325.
42.
BothnerB, ChatmanK, SarkisianM and SiuzdakG. (1995). Liquid chromatography mass spectrometry of antisense oligonucleotides. Bioorg Med Chem Lett, 5:2863–2868.
43.
GilarM. (2001). Analysis and purification of synthetic oligonucleotides by reversed-phase high-performance liquid chromatography with photodiode array and mass spectrometry detection. Anal Biochem, 298:196–206.
44.
HuberCG and KrajeteA. (1999). Analysis of nucleic acids by capillary ion-pair reversed-phase HPLC coupled to negative-ion electrospray ionization mass spectrometry. Anal Chem, 71:3730–3739.
45.
HuberCG and OberacherH. (2001). Analysis of nucleic acids by on-line liquid chromatography-mass spectrometry. Mass Spectrom Rev, 20:310–343.
46.
SmithM and BeckT. (2016). Quantitation of low level coeluting impurity present in a modified oligonucleotide by both LC-MS and NMR. J Pharm Biomed Anal, 118:34–40.
47.
LevinD. (2010). Challenges to validation of methods for double stranded oligonucleotides. In: Podium Presentation at DIA 3rd Oligonucleotide-Based Therapeutics Conference, Bethesda, MD.
48.
BeverlyM, HartsoughK, MachemerL, PavcoP and LockridgeJ. (2006). Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplex. J Chromatogr B Analyt Technol Biomed Life Sci, 835:62–70.
49.
McCarthySM, GilarM and GeblerJ. (2009). Reversed-phase ion-pair liquid chromatography analysis and purification of small interfering RNA. Anal Biochem, 390:181–188.
50.
SzekelyL, KiessigS, SchwartzMA and KalmanF. (2009). Capillary gel electrophoresis of therapeutic oligonucleotides: analysis of single and double-stranded forms. Electrophoresis, 30:1579–1586.
51.
BonillaJV and SrivatsaGS, eds. (2011). Handbook of Analysis of Oligonucleotides and Related Products. CRC Press, Boca Raton, FL.
52.
OkafoG, ElderD and WebbM, eds. (2013). Analysis of Oligonucleotides and Their Related Substances. ILM Publications, Herts, United Kingdom.
53.
LevinAA, YuRZ and GearyRS. (2008). Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Antisense Drug Technology: Principals, Strategies and Applications, 2nd edn. CrookeST, ed. CRC Press, Boca Raton, FL, pp. 183–215.
54.
KriegAM. (2002). CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol, 20:709–760.
55.
SushkoI, SalminaE, PotemkinP, PodaG and TetkoI. (2012). ToxAlerts: a web server of structural alerts for toxic chemicals and compounds with potential adverse reactions. J Chem Inf Model, 52:2310–2316.
